PURPOSE: In some patients with Hodgkin lymphoma (HL), proton beam therapy (PBT) may reduce the risk of radiation-related cardiovascular disease (CVD) and second cancers (SC) compared with photon radiation therapy (RT). Our aim was to identify patients who benefit the most from PBT in terms of predicted 30-year absolute mortality risks (AMR30) from CVD and SC, taking into account individual background, chemotherapy, radiation, and smoking-related risks. METHODS AND MATERIALS: Eighty patients with supradiaphragmatic HL treated with PBT between 2015 and 2019 were replanned using optimal photon RT. To identify patients predicted to derive the greatest benefit from PBT compared with photon RT, doses and AMR30 from CVD and SC of the lung, breast, and esophagus were compared for all patients and across patient subgroups. RESULTS: For patients with mediastinal disease below the origin of the left main coronary artery (n = 66; 82%), PBT reduced the mean dose to the heart, left ventricle, and heart valves by 1.0, 2.7, and 3.6 Gy, respectively. Based on U.S. mortality rates, PBT reduced CVD AMR30 by 0.2%, from 5.9% to 5.7%. The benefit was larger if the mediastinal disease overlapped longitudinally with the heart by ≥40% (n = 23; 29%). PBT reduced the mean dose to the heart, left ventricle, and heart valves by 3.2, 5.6, and 5.1 Gy, respectively, and reduced CVD AMR30 by 0.8%, from 7.0% to 6.2%. For patients with axillary disease (n = 25; 31%), PBT reduced the mean lung dose by 2.8 Gy and lung cancer AMR30 by 0.6%, from 2.7% to 2.1%. Breast and esophageal doses were also lower with PBT, but the effects on AMR30 were negligible. The effect of smoking on CVD and lung cancer AMR30 was much larger than radiation and chemotherapy and the differences between radiation modalities. CONCLUSIONS: The predicted benefit of PBT is not universal and limited to certain categories of patients with lymphoma and lower mediastinal or axillary disease. Smoking cessation should be strongly encouraged in smokers who require thoracic RT.

Guy's and St Thomas' NHS Foundation Trust and School of Cancer and Pharmaceutical Sciences King's College London London United Kingdom

Guy's and St Thomas' NHS Foundation Trust Department of Medical Physics London United Kingdom

Nuffield Department of Population Health University of Oxford Oxford United Kingdom

Nuffield Department of Population Health University of Oxford Oxford United Kingdom; Guy's and St Thomas' NHS Foundation Trust Department of Medical Physics London United Kingdom

Nuffield Department of Population Health University of Oxford Oxford United Kingdom; Manchester Cancer Research Centre University of Manchester Manchester United Kingdom

Nuffield Department of Population Health University of Oxford Oxford United Kingdom; Oxford Cancer Centre Oxford University Hospitals NHS Foundation Trust Oxford United Kingdom

Proton Therapy Center Czech Prague Czech Republic

Proton Therapy Center Czech Prague Czech Republic; Department of Oncology 2nd Faculty of Medicine Charles University Prague and Motol University Hospital Prague Czech Republic

Zobrazit více v PubMed

Cutter DJ, Schaapveld M, Darby SC, et al. Risk of valvular heart disease after treatment for Hodgkin lymphoma. J Natl Cancer Inst. 2015;107 djv008. PubMed PMC

van Nimwegen FA, Schaapveld M, Cutter DJ, et al. Radiation dose-response relationship for risk of coronary heart disease in survivors of Hodgkin lymphoma. J Clin Oncol. 2015;34:235–243. PubMed

Van Nimwegen FA, Ntentas G, Darby SC, et al. Risk of heart failure in survivors of Hodgkin lymphoma: Effects of cardiac exposure to radiation and anthracyclines. Blood. 2017;129:2257–2265. PubMed PMC

Travis LB, Gospodarowicz M, Curtis RE, et al. Lung cancer following chemotherapy and radiotherapy for Hodgkin's disease. J Natl Cancer Inst. 2002;94:182–192. PubMed

Morton LM, Gilbert ES, Stovall M, et al. Risk of esophageal cancer following radiotherapy for Hodgkin lymphoma. Haematologica. 2014;99:e193–e196. PubMed PMC

Maraldo MV, Giusti F, Vogelius IR, et al. Cardiovascular disease after treatment for Hodgkin's lymphoma: An analysis of nine collaborative EORTC-LYSA trials. Lancet Haematol. 2015;2:e492–e502. PubMed

Aleman BMP, Van Den Belt-Dusebout AW, De Bruin ML, et al. Late cardiotoxicity after treatment for Hodgkin lymphoma. Blood. 2007;109:1878–1886. PubMed

Specht L, Yahalom J, Illidge T, et al. Modern radiation therapy for Hodgkin lymphoma: Field and dose guidelines from the International Lymphoma Radiation Oncology Group (ILROG) Int J Radiat Oncol Biol Phys. 2014;89:854–862. PubMed

Voong KR, McSpadden K, Pinnix CC, et al. Dosimetric advantages of a “butterfly” technique for intensity-modulated radiation therapy for young female patients with mediastinal Hodgkin's lymphoma. Radiat Oncol. 2014;9:94. PubMed PMC

Filippi AR, Ragona R, Piva C, et al. Optimized volumetric modulated arc therapy versus 3D-CRT for early stage mediastinal Hodgkin lymphoma without axillary involvement: A comparison of second cancers and heart disease risk. Int J Radiat Oncol Biol Phys. 2015;92:161–168. PubMed

Starke A, Bowden J, Lynn R, et al. Comparison of butterfly volumetric modulated arc therapy to full arc with or without deep inspiration breath hold for the treatment of mediastinal lymphoma. Radiother Oncol. 2018;129:449–455. PubMed

Schaapveld M, Aleman BMP, van Eggermond AM, et al. Second cancer risk up to 40 years after treatment for Hodgkin's lymphoma. N Engl J Med. 2015;373:2499–2511. PubMed

Dores GM, Curtis RE, Dalal NH, Linet MS, Morton LM. Cause-specific mortality following initial chemotherapy in a population-based cohort of patients with classical Hodgkin lymphoma, 2000-2016. J Clin Oncol. 2020;38:4149–4162. PubMed PMC

Lagerlöf I, Holte H, Glimelius I, et al. No excess long-term mortality in stage I-IIA Hodgkin lymphoma patients treated with ABVD and limited field radiotherapy. Br J Haematol. 2020;188:685–691. PubMed

Conway JL, Connors JM, Tyldesley S, et al. Secondary breast cancer risk by radiation volume in women with Hodgkin lymphoma. Int J Radiat Oncol Biol Phys. 2017;97:35–41. PubMed

Hoppe BS, Flampouri S, Su Z, et al. Effective dose reduction to cardiac structures using protons compared with 3DCRT and IMRT in mediastinal Hodgkin lymphoma. Int J Radiat Oncol Biol Phys. 2012;84:449–455. PubMed

Ntentas G, Dedeckova K, Andrlik M, et al. Clinical intensity modulated proton therapy for hodgkin lymphoma: which patients benefit the most? Pract Radiat Oncol. 2019;9:179–187. PubMed PMC

Moreno AC, Gunther JR, Milgrom S, et al. Effect of deep inspiration breath hold on normal tissue sparing with intensity modulated radiation therapy versus proton therapy for mediastinal lymphoma. Adv Radiat Oncol. 2020;5:1255–1266. PubMed PMC

Dabaja BS, Hoppe BS, Plastaras JP, et al. Proton therapy for adults with mediastinal lymphomas: The International Lymphoma Radiation Oncology Group guidelines. Blood. 2018;132:1635–1646. PubMed PMC

Feng M, Moran JM, Koelling T, et al. Development and validation of a heart atlas to study cardiac exposure to radiation following treatment for breast cancer. Int J Radiat Oncol Biol Phys. 2011;79:10–18. PubMed PMC

Duane F, Aznar MC, Bartlett F, et al. A cardiac contouring atlas for radiotherapy. Radiother Oncol. 2017;122:416–422. PubMed PMC

Swarnkar PK, Hafez O, Attallah H, Hall K, Brady J, Mikhaeel G. Is 5 mm CTV-PTV margin adequate for mediastinal lymphoma treated in DIBH? Int J Radiat Oncol Biol Phys. 2020;108:e753.

Levis M, Filippi AR, Fiandra C, et al. Inclusion of heart substructures in the optimization process of volumetric modulated arc therapy techniques may reduce the risk of heart disease in Hodgkin's lymphoma patients. Radiother Oncol. 2019;138:52–58. PubMed

World Health Organization. Mortality database. Available at: https://www.who.int/healthinfo/mortality_data/en/. Accessed January 1, 2017.

De Bruin ML, Dorresteijn LDA, Van't Veer MB, et al. Increased risk of stroke and transient ischemic attack in 5-year survivors of Hodgkin lymphoma. J Natl Cancer Inst. 2009;101:928–937. PubMed

Peto R, Darby S, Deo H, Silcocks P, Whitley E, Doll R. Smoking, smoking cessation, and lung cancer in the UK since 1950: Combination of national statistics with two case-control studies. Br Med J. 2000;321:323–329. PubMed PMC

Field JK, Vulkan D, Davies MPA, et al. Lung cancer mortality reduction by LDCT screening: UKLS randomised trial results and international meta-analysis. Lancet Reg Health Eur. 2021;10 PubMed PMC

Rechner LA, Maraldo MV, Vogelius IR, et al. Life years lost attributable to late effects after radiotherapy for early stage Hodgkin lymphoma: The impact of proton therapy and/or deep inspiration breath hold. Radiother Oncol. 2017;125:41–47. PubMed PMC

Pinnix CC, Smith GL, Milgrom S, et al. Predictors of radiation pneumonitis in patients receiving intensity modulated radiation therapy for Hodgkin and non-Hodgkin lymphoma. Int J Radiat Oncol Biol Phys. 2015;92:175–182. PubMed PMC

Ricardi U, Maraldo MV, Levis M, Parikh RR. Proton therapy for lymphomas: Current state of the art. Onco Targets Ther. 2019;12:8033–8046. PubMed PMC

Tseng YD, Cutter DJ, Plastaras JP, et al. Evidence-based review on the use of proton therapy in lymphoma from the Particle Therapy Cooperative Group (PTCOG) lymphoma subcommittee. Int J Radiat Oncol Biol Phys. 2017;99:825–842. PubMed

Filippi AR, Levis M, Parikh R, Hoppe B. Optimal therapy for early-stage Hodgkin's lymphoma: Risk adapting, response adapting, and role of radiotherapy. Curr Oncol Rep. 2017;19:34. PubMed

Hoppe BS, Bates JE, Mendenhall NP, et al. The meaningless meaning of mean heart dose in mediastinal lymphoma in the modern radiation therapy era. Pract Radiat Oncol. 2020;10:e147–e154. PubMed

Neppelenbroek SIM, Geurts YM, Aleman BMP, et al. Anthracycline exposure and breast cancer risk in female Hodgkin lymphoma survivors. J Clin Oncol. 2021;39:12074.

Veiga LH, Curtis RE, Morton LM, et al. Association of breast cancer risk after childhood cancer with radiation dose to the breast and anthracycline use: A report from the Childhood Cancer Survivor Study. JAMA Pediatr. 2019;173:1171–1179. PubMed PMC

van Nimwegen FA, Schaapveld M, Janus CPM, et al. Cardiovascular disease after Hodgkin lymphoma treatment 40-year disease risk. JAMA Intern Med. 2015;175:1007–1017. PubMed

Cutter DJ, Ramroth J, Diez P, et al. Predicted risks of cardiovascular disease following chemotherapy and radiotherapy in the UK NCRI RAPID trial of positron emission tomography-directed therapy for early-stage Hodgkin lymphoma. J Clin Oncol. 2021;39:3591–3601. PubMed PMC

Ntentas G, Darby SC, Aznar MC, et al. Dose-response relationships for radiation-related heart disease: Impact of uncertainties in cardiac dose reconstruction. Radiother Oncol. 2020;153:155–162. PubMed

Paganetti H. Relating proton treatments to photon treatments via the relative biological effectiveness - Should we revise current clinical practice? Int J Radiat Oncol Biol Phys. 2015;91:892–894. PubMed